BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Biotech Bay

  CRISPR Pioneer Goes Small to Transform Genetic Medicine with Epigenetic Engineering

  Epic Bio aims to transform genetic medicine by developing a new class of drugs that target the epigenome to alter gene expression.

  July 12, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Business

  Knopp, Population Health Launch Areteia to Breathe New Life into Old Molecule

  Backed by biopharma royalty, Areteia Therapeutics will focus on developing an old molecule for a very prevalent disease - asthma.

  July 12, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Pliant and Annexon Seek and Secure Funds for Pulmonary Fibrosis, Autoimmune Treatments

  Annexon and Pliant Therapeutics both made efforts to secure additional financing to support their R&D endeavors.

  July 12, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Bicycle Rides Genentech Partnership to Another Immuno-Oncology Milestone

  Genentech has exercised the second option in its potentially $1.7 billion agreement with Bicycle Therapeutics, triggering a $10 million payment.

  July 12, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Moderna mRNA Portfolio on Track to Hit 2025 Goal with Nipah Virus Trial Launch

  Moderna has dosed its first participant in a Phase I clinical trial of mRNA-1215, a vaccine designed to fight the Nipah virus (NiV), a virus contracted in humans through animals.

  July 12, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Can AAV Gene Therapy Transcend Challenges in the Huntington’s Space?

  uniQure gave a 12-month update on AMT-130, the first-ever AAV gene therapy for HD to enter clinical trials. BioSpace spoke with the company’s president of R&D, Dr. Ricardo Dolmetsch.

  July 12, 2022

   · 

  7 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Nanoscope Zooms in on Retinitis Pigmentosa and Stargardt Disease at ASRS

  Nanoscope Therapeutics will make two presentations at the 2022 ASRS meeting on their gene therapy programs to treat degenerative retinal diseases, retinitis pigmentosa and Stargardt disease.

  July 12, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Verve Tests First One and Done Gene Editing Treatment for Hereditary Killer

  Verve Therapeutics dosed its first patient with VERVE-101, a one-time treatment that aims to permanently lower low-density lipoprotein (LDL) cholesterol in patients and prevent heart disease.

  July 12, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  Aldeyra Scores Late-Stage Clinical Win in Competitive Dry Eye Space

  Aldeyra Therapeutics announced results from a crossover clinical trial, showing that its drug candidate reproxalap was effective in improving ocular redness and tear production in patients with dry eye disease.

  July 12, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Will Biotech Unicorns Soon Be on The Endangered Species List?

  The pace of unicorn creation – which is still quite fast – is slowing as economists predict a coming recession. BioSpace sought out the perspective of four experts.

  July 12, 2022

   · 

  4 min read

   · 

  Gail Dutton